AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) had its price target upped by Roth Capital from $11.25 to $15.00 in a research note released on Thursday. Roth Capital currently has a buy rating on the specialty pharmaceutical company’s stock.

A number of other research firms also recently commented on ACRX. Jefferies Group restated a buy rating on shares of AcelRx Pharmaceuticals in a research report on Friday, June 10th. RBC Capital Markets reaffirmed a positive rating and issued a $6.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Tuesday, August 16th. Cowen and Company reaffirmed a hold rating on shares of AcelRx Pharmaceuticals in a research note on Friday, July 29th. HC Wainwright reaffirmed a buy rating and issued a $7.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Thursday, September 8th. Finally, Stifel Nicolaus cut AcelRx Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $8.20.

Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) opened at 3.47 on Thursday. The stock’s market capitalization is $157.23 million. AcelRx Pharmaceuticals has a 1-year low of $2.40 and a 1-year high of $5.88. The firm has a 50-day moving average price of $3.41 and a 200-day moving average price of $3.29.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its earnings results on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by $0.02. AcelRx Pharmaceuticals had a negative net margin of 111.47% and a negative return on equity of 94.98%. The business earned $4.53 million during the quarter, compared to analysts’ expectations of $2.17 million. On average, equities research analysts forecast that AcelRx Pharmaceuticals will post ($0.91) earnings per share for the current year.

In related news, major shareholder Perceptive Advisors Llc sold 392,850 shares of the business’s stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $3.70, for a total transaction of $1,453,545.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 27.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACRX. Vanguard Group Inc. boosted its position in AcelRx Pharmaceuticals by 15.1% in the second quarter. Vanguard Group Inc. now owns 1,453,751 shares of the specialty pharmaceutical company’s stock valued at $3,911,000 after buying an additional 191,017 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in shares of AcelRx Pharmaceuticals by 73.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 962,026 shares of the specialty pharmaceutical company’s stock worth $2,588,000 after buying an additional 406,974 shares during the period. BlackRock Fund Advisors increased its stake in shares of AcelRx Pharmaceuticals by 1,090.6% in the second quarter. BlackRock Fund Advisors now owns 921,567 shares of the specialty pharmaceutical company’s stock worth $2,479,000 after buying an additional 844,165 shares during the period. State Street Corp increased its stake in shares of AcelRx Pharmaceuticals by 2,427.4% in the second quarter. State Street Corp now owns 424,598 shares of the specialty pharmaceutical company’s stock worth $1,142,000 after buying an additional 407,798 shares during the period. Finally, Bridgeway Capital Management Inc. increased its stake in shares of AcelRx Pharmaceuticals by 26.1% in the second quarter. Bridgeway Capital Management Inc. now owns 281,650 shares of the specialty pharmaceutical company’s stock worth $758,000 after buying an additional 58,250 shares during the period. 35.84% of the stock is owned by hedge funds and other institutional investors.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

5 Day Chart for NASDAQ:ACRX

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.